Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,223
  • Shares Outstanding, K 32,442
  • Annual Sales, $ 54,690 K
  • Annual Income, $ -18,280 K
  • 60-Month Beta 3.00
  • Price/Sales 2.10
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.31
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.43 +0.29%
on 07/13/20
4.33 -20.55%
on 06/19/20
-0.11 (-3.10%)
since 06/12/20
3-Month
2.81 +22.42%
on 05/15/20
4.86 -29.29%
on 04/29/20
+0.56 (+19.44%)
since 04/13/20
52-Week
1.70 +102.35%
on 10/14/19
4.86 -29.29%
on 04/29/20
-0.79 (-18.58%)
since 07/12/19

Most Recent Stories

More News
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development

CARMIEL, Israel, /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX) today announced the appointment of , Ph.D. as the Company's new Vice President, Research and Development,...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

, /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins...

PLX : 3.40 (-2.58%)
Protalix Submits BLA for Fabry Disease Candidate PRX-102

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

SNY : 51.15 (+1.73%)
PLX : 3.40 (-2.58%)
AGEN : 3.61 (-4.75%)
TAK : 17.15 (-0.69%)
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, , /PRNewswire/ --  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020

CARMIEL, , Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 3.40 (-2.58%)
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 3.40 (-2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PLX with:

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Key Turning Points

2nd Resistance Point 3.68
1st Resistance Point 3.59
Last Price 3.40
1st Support Level 3.42
2nd Support Level 3.34

See More

52-Week High 4.86
Fibonacci 61.8% 3.66
Last Price 3.40
Fibonacci 50% 3.28
Fibonacci 38.2% 2.91
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar